|
Co-variable
|
No.
|
Univariate analysis
|
Multivariate analysis
|
|---|
| | |
MST (months)
|
P
|
Variate
|
OR
|
95% CI
|
P
|
|---|
|
Age
| | | | | | | |
|
< 70
|
231
|
22.8
| | | | | |
|
> 70
|
53
|
24.3
|
0.625
| | | | |
|
Gender
| | | | | | | |
|
Male
|
168
|
20.1
| | | | | |
|
Female
|
116
|
32.4
|
0.0086
|
Female
|
1.06
|
0.75-1.58
|
0.75
|
|
Smoking status
| | | | | | | |
|
Yes
|
174
|
20.1
| | | | | |
|
No
|
110
|
33.4
|
0.0012
|
No smoking status
|
0.84
|
0.52-1.24
|
0.39
|
|
ECOG PS
| | | | | | | |
|
0-1
|
238
|
29.5
| | | | | |
|
>2
|
46
|
7.9
|
<.0001
|
PS 0-1
|
0.34
|
0.24-0.50
|
<.0001
|
|
Stage
| | | | | | | |
|
IIIB
|
25
|
30.2
| | | | | |
|
IV
|
259
|
22.5
|
0.269
| | | | |
|
EGFR mutation
| | | | | | | |
|
Mt (+)
|
121
|
39.2
| | | | | |
|
Mt (−)
|
163
|
17.8
|
<.0001
|
Mutant EGFR
|
0.53
|
0.34-0.84
|
0.0069
|
|
PCV
| | | | | | | |
|
< 2.2 ng/ml
|
150
|
38.6
| | | | | |
|
≥ 2.2 ng/ml
|
134
|
15.0
|
<.0001
|
< 2.2 ng/ml
|
0.43
|
0.31-0.59
|
<.0001
|
|
CEA
| | | | | | | |
|
< 5.0 ng/ml
|
108
|
32.6
| | | | | |
|
≥ 5.0 ng/ml
|
176
|
21.0
|
0.036
|
< 5.0 ng/ml
|
0.93
|
0.67-1.26
|
0.63
|
|
Start dates of IT
| | | | | | | |
|
Before 1/ 4/ 2008
|
79
|
34.1
| |
After 1/ 4/ 2008
| | | |
|
After 1/ 4/ 2008
|
205
|
19.3
|
0.0030
| |
0.73
|
0.50-1.15
|
0.07
|
|
EGFR-TKI treatment
| | | | | | | |
|
Yes
|
143
|
33.7
| | | | | |
|
No
|
141
|
15.3
|
<.0001
|
Yes
|
0.76
|
0.50-1.15
|
0.20
|
- IT: initial therapy, PCV: pretreatment CYFRA 21–1 value, Mt(+): mutant EGFR, M(−): wild-type EGFR.
